|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||1.140 - 1.180|
|52 Week Range||1.120 - 2.480|
|Beta (3Y Monthly)||0.94|
|PE Ratio (TTM)||9.03|
|Forward Dividend & Yield||0.04 (2.94%)|
|1y Target Est||1.30|
This article is intended for those of you who are at the beginning of your investing journey and want to start learning about core concepts of fundamental analysis on practical Read More...
In this article, I will take a look at China NT Pharma Group Company Limited’s (HKG:1011) most recent earnings update (30 June 2018) and compare these latest figures against itsRead More...
Aug 21 (Reuters) - China NT Pharma Group Co Ltd: * HY REVENUE FROM CONTINUING OPERATIONS RMB312 MILLION VERSUS RMB314.4 MILLION * HY PROFIT ATTRIBUTABLE RMB82.9 MILLION VERSUS RMB80.7 MILLION Source text ...
April 18 (Reuters) - China NT Pharma Group Co Ltd: * PFENEX AND NT PHARMA ENTER INTO A DEVELOPMENT AND LICENSE AGREEMENT FOR PFENEX'S PF708 THERAPEUTIC EQUIVALENT CANDIDATE TO FORTEO® * PFENEX INC - PFENEX ...
SAN DIEGO and HONG KONG, April 18, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE AMERICAN: PFNX) and China NT Pharma Group Company Limited (NT Pharma) (1011.HK) today announced an agreement under which Pfenex granted NT Pharma non-exclusive development and exclusive commercialization rights to PF708, a teriparatide therapeutic equivalent candidate to Eli Lilly & Company's Forteo®, in Mainland China, Hong Kong, Singapore, Malaysia and Thailand. In accordance with the agreement, Pfenex received a payment of $2.5 million upon signing of the agreement and may be eligible to receive additional payments of up to $22.5 million based on the achievement of certain development, regulatory, and sales-related milestones.
April 6 (Reuters) - China NT Pharma Group Co Ltd: * CHIU YU KANG RESIGNED AS CHIEF FINANCIAL OFFICER * APPOINTS WANG FEI AS CFO Source text for Eikon: Further company coverage:
March 27 (Reuters) - China Nt Pharma Group Co Ltd: * FY REVENUE RMB604.8 MILLION VERSUS RMB359.6 MILLION * FY NET PROFIT ATTRIBUTABLE RMB165.2 MILLION VERSUS RMB116.2 MILLION * FINAL DIVIDEND OF HK3.5 ...
Dec 15 (Reuters) - China Nt Pharma Group Co Ltd: * ENTERS DEAL TO TERMINATE SALES & PROMOTION DEAL, CO TO CEASE LIBOD SALES & PROMOTION FROM DEC. 31, 2017 Source text for Eikon: Further company coverage: ...